Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy

• Autors principals: Xianghui Han (Autor), Zhanyang Luo (Autor), Wenyi Wang (Autor), Peiyong Zheng (Autor), Tian Li (Autor), Zubing Mei (Autor), Jianyi Wang (Autor)
• Format: Llibre
• Publicat: Frontiers Media S.A., 2021-10-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Objective: Rifaximin has been approved for use as a first-line therapy for secondary prophylaxis of hepatic encephalopathy (HE). This article is to update existing evidence on efficacy and safety of rifaximin treatment and prevention for HE.Methods: We systematically searched multiple databases unti...